StockNews.com Initiates Coverage on Pulmatrix (NASDAQ:PULM)

Equities researchers at StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM) in a research report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 12.6 %

Shares of PULM opened at $6.29 on Friday. The company’s fifty day simple moving average is $5.28 and its 200-day simple moving average is $3.21. The company has a market cap of $22.97 million, a P/E ratio of -2.38 and a beta of 1.52. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $8.44.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.